Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome.

Trial Profile

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Major depressive disorder; Metabolic syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2011 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Planned end date changed from 1 Jan 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top